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Abstract
Background: Impaired mitochondrial function and ectopic lipid deposition in skeletal muscle and liver have been linked to
decreased insulin sensitivity. As growth hormone (GH) excess can reduce insulin sensitivity, we examined the impact of
previous acromegaly (AM) on glucose metabolism, lipid storage and muscular ATP turnover.
Participants and Methods: Seven AM (4f/3 m, age: 4664 years, BMI: 2861 kg/m
2) and healthy volunteers (CON: 3f/4 m,
4364 years, 2662 kg/m
2) matched for age and body mass underwent oral glucose testing for assessment of insulin
sensitivity (OGIS) and ß-cell function (adaptation index, ADAP). Whole body oxidative capacity was measured with indirect
calorimetry and spiroergometry. Unidirectional ATP synthetic flux (fATP) was assessed from
31P magnetic resonance
spectroscopy (MRS) of calf muscle. Lipid contents of tibialis anterior (IMCLt) and soleus muscles (IMCLs) and liver (HCL) were
measured with
1H MRS.
Results: Despite comparable GH, insulin-like growth factor-1 (IGF-I) and insulin sensitivity, AM had ,85% lower ADAP
(p,0.01) and ,21% reduced VO2max (p,0.05). fATP was similarly ,25% lower in AM (p,0.05) and related positively to
ADAP (r=0.744, p,0.01), but negatively to BMI (r=20.582, p,0.05). AM had ,3fold higher HCL (p,0.05) while IMCLt and
IMCLs did not differ between the groups.
Conclusions: Humans with a history of acromegaly exhibit reduced insulin secretion, muscular ATP synthesis and oxidative
capacity but elevated liver fat content. This suggests that alterations in ß-cell function and myocellular ATP production may
persist despite normalization of GH secretion after successful treatment of acromegaly.
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Introduction
Acromegaly generally results from slowly growing monoclonal
pituitary adenomas secreting growth hormone (GH). As a result of
its slow and often insidious onset, it frequently remains unrecog-
nized for an extended time, which may give rise to sustained
metabolic alterations [1]. Although improving, the overall stan-
dardized mortality of patients with acromegaly is about 1.5fold
higher compared with the general population [2,3]. Among other
factors, the higher prevalence of glucose intolerance and overt
diabetes mellitus could contribute to the increased mortality [4].
GH stimulates protein anabolism and at the same time
augments lipolysis and reduces insulin-dependent glucose disposal
[5]. Patients with active acromegaly frequently exhibit mild
hepatic [6] and more pronounced muscular insulin resistance
[7,8] which is similar to the metabolic alterations during aging and
states of obesity, inherited risk of or overt type 2 diabetes (T2DM).
Noninvasive magnetic resonance spectroscopy (MRS) made it
possible to identify impaired muscle glucose transport/phosphor-
ylation from monitoring basal and insulin stimulated glucose-6-
phosphate (G6P) concentrations as well as reduced hepatic
glycogen synthesis as key mechanisms underlying reduced glucose
disposal in human insulin resistance [9]. According to the current
paradigm, inherited and environmental factors (elevated glucose
or free fatty acids, FFA) lead to reduced Krebs cycle flux and ATP
synthetic flux (fATP) suggesting impaired mitochondrial oxida-
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tion of lipids in hepatocytes (hepatocellular lipids, HCL) and
myocytes (intramyocellular lipids, IMCL) [10]. Mitochondrial
function is impaired in insulin resistant states including obese
nondiabetic humans, relatives of patients with T2DM and overt
T2DM. Electron microscopic examination revealed abnormalities
of the morphology of muscle mitochondria in a patient with
acromegaly which resolved upon surgical treatment [11].
Recently, evidence was provided that an acute 4-fold increase in
plasma GH not only increased plasma insulin-like growth factor-1
(IGF-I), insulin, glucose and FFA but also shifted fuel selection into
the direction of fat oxidation and stimulated muscle ATP
production rate and citrate synthase activity [12]. However, to
our knowledge, no data are currently available on muscle ATP
synthesis in patients with acromegaly.
In addition, patients with active acromegaly may also feature
altered ß cell function with hyperinsulinemia either resulting from
direct effects of GH/IGF-I or from adaptation to changes in
glucose and FFA availability [13,14]. Glucose intolerance
secondary to acromegaly generally improves following treatment
of the underlying disease, whereas no data are available on ATP
synthesis and ectopic lipid deposition under these conditions.
We tested the hypothesis that the alterations associated with
active acromegaly are completely reversed by normalizing the
endocrine and metabolic environment implicating normal fATP.
To this end, we measured insulin sensitivity and ß cell function as
well as whole body energy expenditure and physical fitness.
Employing noninvasive multinuclear magnetic resonance spec-
troscopy (MRS), we further assessed in vivo fATP, flux through
creatine kinase (fCK) and glucose metabolites (G6P) in skeletal
muscle as well as ectopic lipid deposition (IMCL, HCL) in patients
with prior acromegaly.
Methods
Volunteers
We included seven patients with prior acromegaly (AM) and
seven healthy subjects (CON) matched for age, BMI and physical
activity [15]. The mean duration between assumed clinical onset
based on typical symptoms and diagnosis of acromegaly was
1064 years. The participants had no first-degree relatives with
T2DM. The mean interval between successful treatment until
inclusion into the study was 1463 years, but at least 7 years. All
but one patient underwent transsphenoidal surgery for GH-
secreting pituitary adenomas, one patient also received adjuvant
radiotherapy and gamma knife treatment. Two of them required
replacement of hormones (thyroid hormone, hydrocortisone and
in one case additionally estrogen and gestagens) due to
postoperative hypophyseal insufficiency. Three patients had been
on pre- and postsurgical treatment with somatostatin analogues
and bromocriptin, but only one patient required pharmacological
treatment of acromegaly during the last two years. This patient
was on octreotide and pegvisomant, had normal GH and IGF-I
concentrations and similar insulin secretion compared to the rest
of the group, but was glucose intolerant based on the 2-h plasma
glucose concentration during the oGTT. Fasting plasma concen-
trations of IGF-I and GH and suppression during OGTT were
within the normal range at repeated measurements during the last
years indicating successful treatment in patients with acromegaly.
Experimental protocol
The protocol was approved by the local human ethical board
(Ethics Committee of the Medical University of Vienna), and
written informed consent was obtained from each volunteer. All
participants were instructed to ingest a mixed diet (25–30 kcal per
kg bodyweight per day consisting of 60% carbohydrates, 25% fat,
15% proteins) for three days prior to the studies. They refrained
from any physical exercise for three days and fasted for 12 hours
and did not take any medications before the experiments. A 75-
gram oral glucose tolerance test (OGTT) was performed to assess
glucose tolerance, insulin sensitivity and secretion. Magnetic
resonance spectroscopy (MRS) and respiratory gas exchange
measurements were carried out on separate days with intervals of
at least one week each at identical daytimes in the morning.
MRS
All measurements were performed during resting conditions in
participants lying supine inside a 3-T spectrometer (Bruker,
Germany) using a 10-cm circular double resonant surface coil for
1H/
31P measurements [16].
31P MRS allowed determination of
fATP from the exchange between inorganic phosphate (Pi) and
ATP (PiRATP) applying saturation transfer to calf muscle as
described [16,17]. In analogous fashion, the exchange between
phosphocreatine (PCr) and ATP (PCrRATP) was used to
calculate total (cytosolic and mitochondrial) flux through creatine
kinases (fCK) [18,19]. Intramyocellular concentrations of G6P, Pi,
PCr and phosphodiesters (PDE) were measured from the ratio of
the respective integrated peak intensities and ß-ATP resonance
intensity in spectra without inversion and saturation assuming
constant ATP concentrations of 5.5 mmol/l muscle [20].
1H MRS
allowed to measure IMCL in soleus and tibialis muscles [21] and
HCL as described [22].
OGTT
The volunteers drank a solution containing 75 grams of glucose
and venous blood samples were collected before and in 30-min
intervals during 150 min for measurements of plasma glucose,
insulin, C-peptide. Plasma concentrations of insulin, C-peptide
and IGF-I were determined by double antibody radio immuno-
assay [22]. Further, dynamic insulin sensitivity were assessed with
the OGIS [23], a measure of glucose clearance which has been
validated against insulin sensitivity obtained from the euglycemic-
hyperinsulinemic clamp [24]. Insulin secretion in relation to
ambient insulin sensitivity was assessed with the insulinogenic
index (ISEC), an indicator of first phase insulin secretion which is
calculated as the ratio between the supra-basal increments at
30 min of insulin and glucose concentration [24]. The adaptation
index (ADAP) is based on the areas under the concentration curves
of plasma glucose and C-peptide during the OGTT and is a
marker of responsive ß cell function [25].
Respiratory gas exchange measurement
After a 30-min resting period, measurements were performed
on subjects in supine position under a canopy using an open-air
spirometry system (Jaeger/Viasys MasterScreen CPX. Wuerz-
burg. Germany) combined with continuous heart rate recording
(Sporttester PE4000, Polar Electro, Kempele, Finland). Resting
energy expenditure (REE, kcal/24 h) was assessed from two 30-
min sets which were separated by 15-min breaks in a quiet air
conditioned laboratory (21uC) using the equation: 3.91 VO2
21.10 VCO2 – 1.93 N [26,27]. Thereafter, the volunteers
performed an incremental exercise test on an electronically-braked
cycle ergometer (Lode Excalibur Sport, Groningen, Netherlands).
The exercise test started at an initial level of 20 W followed by 7,
10, 15 or 20 W increments every min until exhaustion. The
respiratory compensation point (RCP) was determined from
incremental testing as described previously [28].
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Data are presented as means6SEM. Statistical comparisons
between study groups were performed using two-tailed Student’s t
tests or the Mann-Whitney-Wilcoxon test for parameters not
having a normal distribution (ADAP, ISEC, GH, IGF-I, HCL,
IMCLs) as assessed from the Levene test. Linear correlations are
Pearson product-moment correlations. Differences were consid-
ered significant at the 5% level.
Results
Anthropometric and laboratory data are summarized in
Table 1. In AM, fasting plasma concentrations of IGF-I and
GH did not differ from CON and were within the normal range
indicating successful treatment of the patients with previous
acromegaly. Fasting plasma glucose was ,17% higher in AM
(p,0.05) and four patients had impaired fasting glucose (defined
as fasting plasma glucose levels of 5.6 to 6.9 mmol/l), whereas
plasma insulin and C-peptide were not different. All but one
participant had normal glucose tolerance (as defined by the 2-h
plasma glucose concentration less than 7.8 mmol/l the during
OGTT) during active acromegaly and at follow-up visits following
successful treatment. Fasting plasma insulin and C-peptide related
positively to IGF-I levels (r=0.552 and r=0.646, p,0.05). Insulin
secretion indices (ADAP, ISEC) were ,85% lower in AM than in
CON (p,0.05). Insulin sensitivity (OGIS) was comparable
between groups (Figure 1) and correlated negatively with fasting
plasma FFA (r=20.744, p,0.05). FFA further related positively
to GH levels (r=0.782, p,0.01).
Parameters of whole body oxidative capacity during resting and
exercise are summarized in Table 2. REE, resting O2
consumption (AM: 0.2560.02, CON: 0.2860.02 l.min
21) and
CO2 production (AM: 0.2060.01, CON: 0.2360.02 l.min
21), the
respiratory quotient (RQ), as well as the derived oxidation rates for
glucose (GOX) lipids (LOX) and proteins (POX) were compara-
ble. GOX related negatively to FFA (r=20.718, p,0.05) and GH
(r=20.729, p,0.05) and LOX related positively to skeletal
muscle fATP (r=0.637, p,0.05).
AM had ,21% lower maximal oxygen uptake (VO2max) and
oxygen uptake at the RCP (VO2rcp) (p,0.05, Figure 1), the
respective power output measures tended to be lower in AM but
did not reach significance.
Intramyocellular G-6-P (both groups: 0.0960.01 mmol/L) and
pH (7.0560.0) were comparable in both groups. Skeletal muscle
fATP was ,25% lower in AM (p,0.05, Figure 1) and related
positively to ADAP (r=0.744, p,0.01) and ISEC (r=0.687,
p,0.01) and negatively to BMI (r=20.582, p,0.05). The rate
constant of ATP synthesis (k1) was ,25% lower in AM (AM:
0.0660.01, CON: 0.0860.01 s
21,p ,0.01), PCr/Pi ratios (AM:
7.760.6, CON: 7.360.2) and fCK (AM: 317623, CON:
350613 mmol.l
21.min
21) were comparable.
HCL was three-fold higher in AM than in CON (Figure 2).
IMCLs and IMCLt did not differ between the groups. IMCLs, but
not IMCLt, related negatively to insulin sensitivity (r=20.799,
p,0.001). IMCLt, but not IMCLs, related positively to plasma
IGF-I (r=0.726, p,0.01) (Figure 3).
Figure 1. Whole-body insulin sensitivity, maximal oxygen consumption and muscle mitochondrial ATP production (means6SEM):
(A) OGIS (B) VO2max (p,0.05) and (C) flux through ATP synthesis (fATP) (p,0.05) in 7 subjects with previous acromegaly (AM, full
bars) and 7 age- and body mass index-matched controls (CON, empty bars).
doi:10.1371/journal.pone.0003958.g001
Table 1. Anthropometric and laboratory data (means6SEM)
in subjects with prior acromegaly (AM) and controls (CON).
AM CON
N (f/m) 4/3 3/4
Age (years) 46644 3 64
BMI (kg/m
2) 27.861.3 25.661.5
Waist-to-hip ratio 0.8660.02 0.8660.04
HbA1c (%) 5.460.2 5.360.1
Insulin-like growth factor-1
(IGF-I, ng/ml)
227659 141618
Growth hormone (GH, U/ml) 2.460.6 3.361.5
Fasting glucose (mmol/l) 5.560.2 4.760.1 *
2-hour glucose (mmol/l) 6.260.9 5.260.4
Fasting insulin (pmol/l) 43.468.2 37.265.7
Fasting C-peptide (pmol/ml) 2.460.3 1.960.3
Fasting plasma FFA (mmol/l) 368696 285629
ISEC (610
26) 0.860.3 6.561.5 1
ADAP (l.min
21.m
22.10
23) 0.460.2 2.760.6 1
*P,0.01.
1P,0.05 vs. AM.
doi:10.1371/journal.pone.0003958.t001
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Humans with a history of acromegaly exhibit normal whole
body insulin sensitivity despite impaired ß cell function. Nonethe-
less, noninvasive measurements unmasked abnormalities in energy
metabolism such as impaired muscular ATP synthesis during
resting conditions, reduced maximal oxygen consumption and
increased hepatic triglyceride contents years after successful
treatment of acromegaly. This is similar to the reduced
mitochondrial function observed in elderly or type 2 diabetic
patients [17,29,30].
This study is consistent with previous reports showing that
whole-body insulin sensitivity is normal after cure of acromegaly
[31,32]. It is well known that reduced insulin-sensitive muscular
glucose uptake in untreated acromegalic patients is mediated by
prolonged increases in GH and IGF-I [8,33]. The cellular
mechanisms of acromegaly-associated insulin resistance involve
direct GH-mediated expression of suppressors of cytokine
signaling (SOCS-1/-6) [34] or indirect activation of nutrient-
sensing pathways [35] due to excessive lipolysis [20] and
proteolysis [36,37]. Dietary proteins and amino acids promote
insulin resistance via the mammalian target of rapamycin, a
nutrient sensor that activates a negative feedback loop toward
insulin receptor substrate-1 signalling [37]. But for the most part,
increased plasma FFA can cause serine phosphorylation of insulin-
receptors substrate-1 and thereby inhibit proximal steps of insulin
signaling [38]. Accordingly, in the present study, FFA related
positively to plasma levels of GH and negatively to insulin
sensitivity. In addition, therapeutic interventions may also affect
insulin action and secretion: first, transsphenoidal surgery can
either be not sufficient to normalize GH and IGF-I secretion or
alternatively lead to deficiency of other hypophyseal hormones
involved in metabolism [39] and second, somatostatin analogues and
GH receptor analogues can specifically affect insulin secretion or
glucose metabolism. In the present study, only one patient was on
acromegaly-specific medication, but all patients had plasma concen-
trations of GH, IGF-I, other hypophyseal hormones as well as
circulating FFA which were not different from the matched control
group. Thus, it is not surprising that whole-body insulin sensitivity
was not impaired in these patients with a history of acromegaly.
Table 2. Expired gas analysis during resting (indirect
calorimetry) and exercise (spiroergometry).
AM CON
Resting energy expenditure (kcal/24 h) 16786118 18896167
Glucose oxidation (mg.kg
21.min
21) 1.560.2 1.460.3
Lipid oxidation (mg.kg
21.min
21) 0.660.1 0.760.1
Protein oxidation (mg.kg
21.min
21) 0.760.1 0.760.2
Respiratory quotient 0.8460.04 0.8360.04
VO2max (ml.kg
21.min
21) 27623 4 61 1
Maximal power output (W) 180626 229617
VO2rcp (ml.kg
21.min
21) 22622 8 61 1
Power output at RCP (W) 130616 179612
Fasting substrate oxidation and parameters of physical fitness (means6SEM) in
subjects with prior acromegaly (AM) and controls (CON).
1P,0.05 vs. AM.
doi:10.1371/journal.pone.0003958.t002
Figure 2. Ectopic lipid deposition: (A) in M.soleus (IMCLs), (B) M.tibialis ant. (IMCLt) and (C) in the liver (HCL) (p,0.05).
doi:10.1371/journal.pone.0003958.g002
Figure 3. Relationship between ectopic lipid content of tibialis
muscle (IMCLt) and plasma concentrations of insulin-like
growth factor-1 (IGF-I) in 7 subjects with previous acromegaly
(AM, black squares) and 7 age- and body mass index-matched
controls (CON, grey squares) (r=0.726, p,0.05).
doi:10.1371/journal.pone.0003958.g003
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exhibited severe impairment of dynamic insulin secretion. Both
insulin and IGF-I are important regulators of ß cell development,
ß cell mass and function [40,41]. Chronic GH/IGF-I excess
during active acromegaly induces hyperinsulinemia which is likely
mediated by elevation of plasma glucose as well as by direct ß
cytotrophic effects [13,41]. Accordingly, IGF-I levels related
positively to fasting plasma concentrations of insulin and C-
peptide in the present study. During early stages of T2DM,
exhaustive stimulation of ß cells to counterbalance insulin
resistance precedes the progressive ß cell failure involving impaired
function and loss of ß cell mass [42]. The pathophysiological
mechanisms might involve excess of nutrient availability, partic-
ularly of FFA [43], hyperglycemia, adipocytokine-mediated
endoplasmic reticulum stress (release of reactive oxygen species)
and cellular inflammation [44]. These mechanisms could also
apply for the present study, assuming that the participants
acquired their ß cell defect during active acromegaly. Ultimately,
insulin secretory responses rely on intact mitochondrial function to
provide for sufficient ATP and - as recently demonstrated - GTP
for glucose-stimulated insulin secretion [45]. Thus, mitochondrial
impairment of ß cells could also underly reduced adaptive insulin
secretion.
During active acromegaly, there is evidence that GH acutely
reduces glucose oxidation and impairs glucose disposal directing
glucose fluxes into the non-oxidative pathway. In line with this
contention, rates of lipid oxidation and non-oxidative glucose
metabolism were found to be increased while oxidative glucose
metabolism was decreased [31,46]. However, this seems to hold
true for high plasma FFA concentrations because no reduction in
oxidative metabolism was detected in the presence of normal
plasma FFA [8,47]. Accordingly, in the present study GOX
related negatively to FFA and GH. However, resting energy
expenditure, as well as substrate specific oxidation rates did not
differ between the study groups. On the other hand, despite
comparable physical activity oxygen uptake during maximal
exhaustion and at the RCP were reduced in the group of patients
with previous acromegaly. The RCP marks the onset of
hyperventilation during incremental exercise mainly driven by
the onset of lactic acidosis [48] and thus is a good marker of
oxidative capacity.
To our knowledge, no previous data are available on in vivo
ATP production in humans with prior acromegaly. Here, such
humans showed reduction of ATP synthetic flux rates (fATP) to a
similar extent as reported in other states of impaired oxidative
phosphorylation [30,49]. This is also reflected by the positive
relationship between fasting whole body lipid oxidation and
skeletal muscle fATP. It has been shown that in combination with
endurance training, GH injections can enhance the positive effects
of physical activity on muscle mitochondrial enzyme activities
[50]. A recent report also investigated the sole effects of continuous
GH infusion for 14 h and found that GH not only induced several
mitochondrial genes but also promoted an increase in mitochon-
drial capacity in particular for fat oxidation and a shift in whole
body fuel utilization toward enhanced fat utilisation [12].
Augmented lipid availability leads to accumulation of lipid
metabolites such as long-chain fatty acyl CoA, diacylglycerols
and ceramides which are known to impair insulin signalling and
damage mitochondria [10]. In the present study, insulin sensitivity
related negatively to IMCL of soleus muscle, although IMCL were
comparable in both groups. Nevertheless, the relationship between
IMCL of tibialis muscle and IGF-I suggests that active acromegaly
could favour prolonged lipid accumulation with long-term
deleterious effects on mitochondria. On the other hand, patients
with prior acromegaly had markedly increased HCL. In the
absence of alcohol intake or other hepatotoxic agents, HCL
accumulation, i.e. steatosis or non-alcoholic fatty liver [51], could
be a key factor in the development of insulin resistance and T2DM
[52]. These data are in line with a previous study reporting 4–
7fold higher HCL, but unchanged IMCL contents in T2DM with
impaired fATP [30]. Thus, excessive hepatic lipid storage relates
to insulin resistance, hepatocellular mitochondrial dysmorphology,
depletion of mtDNA and decreased activity of ETC and could be
interpreted as mitochondrial impairment of hepatocytes [53].
Of note, one limitation resides in the fact that the study design
does not allow discrimination whether these abnormalities directly
result from the previous GH/IGF-I excess or develop as a long-
term consequence of metabolic alterations due to glucose, lipids
and adipocytokines, because no patients with active acromegaly
were included in this study. It is also impossible to sort out whether
dysfunction of ß cells or of myocytes occurs first and to which
extent these alterations are interrelated. Furthermore, the
observed reduction in basal ATP synthesis flux does not equal
mitochondrial dysfunction but could reflect a decreased ATP
demand, a decreased mitochondrial content, and/or an impaired
intrinsic mitochondrial function [54].
Long-term prospective studies in patients before and after
successful acromegaly treatment are required to address these
issues. Regardless of the cause and sequence of abnormalities in
humans with prior acromegaly, the sustained disruption of ATP
synthesis along with severely impaired ß cell function could
contribute to an increased risk of this population for developing
diabetes despite successful acromegaly therapy.
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